{"meshTags":["Humans","Immunotherapy","Neoadjuvant Therapy","Pancreatic Neoplasms","Prognosis","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Protons","ras Proteins"],"meshMinor":["Humans","Immunotherapy","Neoadjuvant Therapy","Pancreatic Neoplasms","Prognosis","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Protons","ras Proteins"],"publicationTypes":["Journal Article"],"abstract":"Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, USA. We present the summary of the findings from Abstracts #4020, #4021, #4040 and #4049 and discuss the impact on this group of patients.Â ","title":"Adjuvant therapy of pancreatic cancer.","pubmedId":"22797387"}